SAGE-217
Phase 3Small molecule
BiogenSAGE-217 is one of 154 small molecule programs targeting Insomnia. It is currently in Phase 3.
5
Indications
13
Total Trials
0
Active Trials
153
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
386 competitors in Major Depressive Disorder
#DrugCompanyPhaseTrials
1Seroquel
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Elavil
AstraZenecaPhase 3
Daliresp
AstraZenecaPhase 3
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
Ketalar
Boehringer IngelheimPhase 3
Latuda
SSunovion Respiratory Development Inc.
Phase 3
Versed
CConrado Roberto Hoffmann Filho
Phase 3
Risperdal
WWim Janssens
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Major Depressive Disorder7 trials
Show 4 more trials
Postpartum Depression2 trials
Insomnia1 trial
Major Depressive Episode1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SAGE-217. EMBL-EBI & Wellcome Sanger Institute.
- [4]